Browse by Medical Category
Research at Mass General
Welcome to the website for the laboratory of Dr. Maryam Asgari at the Department of Dermatology at Massachusetts General Hospital and the Department of Health Population at (DPM) Harvard Medical School. Our unit conducts clinical and epidemiologic research related to skin diseases including research on the causes, prevention, evaluation, and management of and interventions for skin diseases in human populations. The range of projects in our laboratory vary from pharmacoepidemiology and skin cancer risk; interactions of immunity and skin cancer; vitamin D and skin health; adverse outcomes among moderate-to-severe psoriasis patients; and patient-centered outcomes including patient satisfaction in skin cancer treatment.
Meet Our Team
Maryam M. Asgari, MD, MPHPrincipal InvestigatorAssociate Professor of Dermatology at Harvard Medical School
Maryam M. Asgari, MD, MPH is a board-certified dermatologist, epidemiologist, and Mohs micrographic surgeon who specializes in the care of patients with skin cancer. She has published more than 70 papers in peer-reviewed journals, has had leadership roles in several professional associations including the American Academy of Dermatology, and has delivered more than 100 academic presentations. She is also the Director of the High Risk Skin Cancer Clinic at Massachusetts General Hospital.
Katherine LevandoskiResearch Assistant
Katherine Levandoski is a research assistant. She received her bachelor's degree in Molecular, Cellular, and Developmental Biology from Yale University. She is a medical student at the Johns Hopkins School of Medicine. She is pursuing a year of research with the PORES Unit prior to completing her final year of medical school. Her current research is focused the epidemiology of skin cncer with ongoing projects related to the pharmaacoepidemiology and skin cancer and the establishment of an institutional skin cancer registry.
Jessica FengResearch Fellow
Jessica Feng is a research fellow. She received her bachelor's degree in Cell and Molecular Biology from Brown University. She is a medical student at the University of Massachusetts Medical School and is pursuing a year of research with the PORES Unit prior to completing her final year of medical school. Her current research is focused on the epidemiology of skin cancer, with ongoing projects investigating pharmacoepidemiology and skin cancer risk. Jessica is especially interested in the intersection of preventive medicine and dermatology.
Yuhree KimPostdoctoral Research Fellow
Yuhree Kim joined the PORES Unit in 2017 as a postdoctoral research fellow. She received her Master's degree in Public Health from Johns Hopkins School of Public Health and her medical degree from Seoul National University in South Korea. Her research interests include clinical and epidemiologic research concerning patient-centered comprehensive care and preventive medicine for skin cancer. Her current research is focused on the epidemiology of skin cancer, with ongoing projects related to Vitamin D and skin health, and interactions of immunity and skin cancer.
Ongoing Research SupportAn Observational Study Comparing Topical 5-FU vs. Imiquimod for Prevention Keratinocyte CarcinomasThe major goal is to examine the effectiveness of the two most widely used topical field-treatments for treatment of actinic keratoses, 5-fluorouracil and imiquimod, in preventing non-melanoma skin cancer and subsequent actinic keratoses.Role: Asgari, Principal Investigator: R03AR064014: 01/01/13-04/30/16
Genome-wide association study of cutaneous squamous cell carcinomaThis study seeks to conduct a genome-wide association study of 6,179 participants within the Research Program in Genes and Environmental Health (RPGEH) cohort members diagnosed with a cutaneous SCC and 101,348 controls to search for new sequence variants that confer risk of cutaneous SCC.Role: Asgari, Principal Investigator; R01CA166672:01/01/13 - 06/30/17
Administrative Supplement to ResearchThe major goal of this supplemental funding was to examine the impact of sex/gender differences in human health by extending that analysis to examine the role of mitochondrial genetic variation and its effect on the risk of SCC in men and women.Role: Asgari, Principal Investigator: 10/1/15 - 10/01/16
The Incidence of Safety Events in the Real World Population of Patients with Moderate to Severe PsoriasisThe main goal is to gather epidemiologic data related to safety events in patients with moderate to severe psoriasis.Role: Asgari, Principal Investigator: Pfizer Inc.: 01/01/13-06/30/16Using Genomic Technologies to Comprehensively Characterize Acral MelanomasThis study seeks to comprehensively characterize the genomics of acral melanomas in to help identify new points of therapeutic intervention.Role: Asgari, Principal Investigator: Melanoma Research Alliance: Team Science Award: 11/15/13-06/30/15 An Observational Study Comparing Topical 5-FU vs. Imiquimod for Prevention Keratinocyte Carcinomas Cohort Study to Assess the Risk of Non-Melanoma Skin Cancer in Adult Patients with Atopic Dermatitis Exposed to Topical Calcineurin InhibitorsRole: Asgari, Principal Investigator: Valeant Pharmaceuticals:08/1/14-07/31/18
Please view Dr. Asgari's publications at Pub Med
Gilkey MB, Mays D, Asgari MM, Kornides ML, McRee AL. Parental Support for Age-based Indoor Tanning Restrictions. Am J Prev Med. 2017 May 8. pii: S0749-3797(17)30201-5. doi: 10.1016/j.amepre.2017.03.011. [Epub ahead of print]PMID:28522236
Storer M, Zhu Z, Sokil M, Ford M, Neugebauer R, Asgari MM. Community-Based Practice Variations in Topical Treatment of Actinic Keratoses. JAMA Dermatol. 2017 May 1;153(5):468-470. doi: 10.1001/jamadermatol.2016.6251. No abstract available.PMID: 28384712
Yesantharao P, Wang W, Ioannidis NM, Demehri S, Whittemore AS, Asgari MM. Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system. Hum Immunol. 2017 Apr;78(4):327-335. doi: 10.1016/j.humimm.2017.02.002. Epub 2017 Feb 7. Review. PMID: 28185865
Asgari MM, Ray GT, Geier JL, Quesenberry CP. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017 Apr;76(4):632-638. doi: 10.1016/j.jaad.2016.10.006. Epub 2017 Feb 3.PMID: 28162854
Moshiri AS, Doumani R, Yelistratova L, Blom A, Lachance K, Shinohara MM, Delaney M, Chang O, McArdle S, Thomas H, Asgari MM, Huang ML, Schwartz SM, Nghiem P.Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. J Invest Dermatol. 2017 Apr;137(4):819-827. doi: 10.1016/j.jid.2016.10.028. Epub 2016 Nov 1.
Levandoski KA, Nazarian RM, Asgari MM. Hypertrophic lichen planus mimicking squamous cell carcinoma: The importance of clinicopathologic correlation. JAAD Case Rep. 2017 Mar 21;3(2):151-154. doi: 10.1016/j.jdcr.2017.01.020. eCollection 2017 Mar. No abstract available
Asgari MM, Toland AE, Arron ST. IRF4 Polymorphism Is Associated with Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients: A Pigment-Independent Phenomenon. J Invest Dermatol. 2017 Jan;137(1):251-253. doi: 10.1016/j.jid.2016.07.038. Epub 2016 Aug 24. No abstract available. PMID: 27566401
Whittemore AS, Wang W, Jorgenson E, Asgari MM. A GWAS of Cutaneous Squamous Cell Carcinoma-Letter. Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1534. No abstract available. PMID: 27803070
Asgari MM. Utility and Limitations of Large Population-Based Data for Skin Cancer Outcomes. J Invest Dermatol. 2016 Nov;136(11):2128-2130. doi: 10.1016/j.jid.2016.07.031.PMID: 27772547
Ray GT, Kulldorff M, Asgari MM. Geographic Clusters of Basal Cell Carcinoma in a Northern California Health Plan Population. JAMA Dermatol. 2016 Nov 1;152(11):1218-1224. doi: 10.1001/jamadermatol.2016.2536. PMID: 27439152
Curtis JR, Harrold LR, Asgari MM, Deodhar A, Salman C, Gelfand JM, Wu JJ, Herrinton LJ. Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting. 2016 Fall;20(4):4-10. doi: 10.7812/TPP/15-151. Epub 2016 Jul 29. PMID: 27479952
Mansh M, Binstock M, Williams K, Hafeez F, Kim J, Glidden D, Boettger R, Hays S, Kukreja J, Golden J, Asgari MM, Chin-Hong P, Singer JP, Arron ST. Voriconazole Exposure and Risk of Cutaneous Squamous Cell Carcinoma, Aspergillus Colonization, Invasive Aspergillosis and Death in Lung Transplant Recipients. Am J Transplant. 2016 Jan; 16(1):262-70.Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012. JAMA Dermatol. 2015 Sep 1; 151(9):976-81.Moore MM, Geller AC, Warton EM, Schwalbe J, Asgari MM. Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011. J Am Acad Dermatol. 2015 Oct; 73(4):630-6.Asgari MM, Arron ST, Warton EM, Quesenberry CP, Weisshaar D. Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs). J Am Acad Dermatol. 2015 Sep; 73(3):444-50.Davis RL, Gallagher MA, Asgari MM, Eide MJ, Margolis DJ, Macy E, Burmester JK, Selvam N, Boscarino JA, Cromwell LF, Feigelson HS, Kuntz JL, Pawloski PA, Penfold RB, Raebel MA, Sridhar G, Wu A, La Grenade LA, Pacanowski MA, Pinheiro SP. Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases. Pharmacoepidemiol Drug Saf. 2015 Jul; 24(7):684-92.Asgari MM, Warton EM, Whittemore AS. Family history of skin cancer is associated with increased risk of cutaneous squamous cell carcinoma. Dermatol Surg. 2015 Apr; 41(4):481-6.Hoffmann TJ, Sakoda LC, Shen L, Jorgenson E, Habel LA, Liu J, Kvale MN, Asgari MM, Banda Y, Corley D, Kushi LH, Quesenberry CP, Schaefer C, Van Den Eeden SK, Risch N, Witte JS. Imputation of the Rare HOXB13 G84E Mutation and Cancer Risk in a Large Population-Based Cohort. PLoS Genet. 2015 Jan; 11 1):e100493.Huynh JC, Asgari MM, Moore MM. Sebotropic eruption associated with use of oral kava kava supplement. Clin Exp Dermatol. 2014 Oct; 39(7):816-8.
Author Interview: Trends in Basal Cell Carcinoma Incidence in High-Risk Patients (JAMA Dermatology) (04:03) Listen under author interviews, Maryam M. Asgari, MD, scroll down to her interview dated September 1, 2015.
8/31/15 What to Watch for After Skin Cancer
Wall Street Journal: Maryam Asgari, MD, MGH dermatologist, and director of the High Risk Skin Cancer Clinic, comments on study results and the importance of skin cancer screenings.
The Patient-Oriented Research in the Epidemiology of Skin diseases (PORES) unit at the Massachusetts General Hospital/Harvard Medical School has an immediate opening for a postdoctoral candidate to study the genomics of non-melanoma skin cancer. Applicants must have an M.D. and/or Ph.D. degree and optimally will have experience with epidemiologic and statistical data analysis. Strong quantitative skills and practical experience working with large-scale datasets and applying epidemiologic tools are a plus. Experience in systems biology, systems genetics and genomics research is essential. Interested candidates who have previous experience in statistics, bioinformatics, epidemiology, genetic epidemiology, and genomics of complex human diseases (required for this position) should send their cover-letter, CV and the names of 3 references to PORES@mgh.harvard.edu The research will be done under the mentorship of faculty member Maryam Asgari, MD MPH.Starting date: July 1, 2017 (can be earlier, depending on candidate and circumstances)Duration: The post-doctoral fellow will be funded for up to three years.Post-doctoral fellow must be a US Citizen or green-card holder. MGH/HMS is a committed Equal Opportunity/Affirmative Action Employer. Minorities, women, handicapped and veterans are encouraged to apply.
Also, please apply online at http://www.massgeneral.org/careers/jobsearch.aspx , job listing # 3032295.
Patient Oriented Research in the Epidemiology of Skin Diseases (PORES)
Maryam M. Asgari, MD, MPHPrincipal Investigator
Harvard Medical School Department of Population Medicine 401 Park Drive, Suite 401 Boston, MA 02215
Back to Top